The best deals are not always the quickest to close, as Teva Pharmaceuticals learned in 2016 after its much-lauded acquisition of Allergan’s generic business, Actavis Generics. In its acquisition of ...

This comes nine years after the company made bold moves overseas as it acquired Actavis’ UK and Actavis Ireland businesses from Teva Pharmaceutical Industries Ltd for around $769 million. VCCircle ...

Not content with buying up a big chunk of the world’s generics market with its $40.5 billion merger with Actavis, Teva is muscling in on biosimilars with a deal with South Korea’s Celltrion.

Teva has agreed to pay a whopping $1.2 billion ... Other cases in the US include the FTC's pursuit of AbbVie subsidiary Solvay and Actavis unit Watson on testosterone replacement therapy product ...

Teva Pharmaceutical (NYSE ... the company's decision to rely heavily on U.S. generics via its $41B buyout of Actavis Generics in 2016. "Upon further reflection and dialogue with management ...